Top

Published in:

01-04-2019 | Oncology

Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival

Authors: Steffen Marquardt, Martha M. Kirstein, Roland Brüning, Martin Zeile, Pier Francesco Ferrucci, Warner Prevoo, Boris Radeleff, Hervé Trillaud, Lambros Tselikas, Emilio Vicente, Philipp Wiggermann, Michael P. Manns, Arndt Vogel, Frank K. Wacker

Published in: European Radiology | Issue 4/2019

Abstract

Objectives

Cholangiocarcinoma is the second most common primary liver tumour with a poor overall prognosis. Percutaneous hepatic perfusion (PHP) is a directed therapy for primary and secondary liver malignancies, and its efficacy and safety have been shown in different entities. The purpose of this study was to prove the safety and efficacy of PHP in patients with unresectable intrahepatic cholangiocarcinoma (iCCA).

Patients and methods

We retrospectively reviewed data from 15 patients with unresectable iCCA treated with PHP in nine different hospitals throughout Europe. Overall response rates (ORR) were assessed according to response evaluation criteria in solid tumours (RECIST1.1). Overall survival (OS), progression-free survival (PFS) and hepatic PFS (hPFS) were analysed using the Kaplan-Meier estimation. Adverse events (AEs) and toxicity were evaluated.

Results

Fifteen patients were treated with 26 PHPs. ORR was 20%, disease control was achieved in 53% after the first PHP. Median OS was 26.9 months from initial diagnosis and 7.6 months from first PHP. Median PFS and hPFS were 122 and 131 days, respectively. Patients with liver-only disease had a significantly longer median OS compared to patients with locoregional lymph node metastases (12.9 vs. 4.8 months, respectively; p < 0.01). Haematological toxicity was common, but manageable. No AEs of grade 3 or 4 occurred during the procedures.

Discussion

PHP is a standardised and safe procedure that provides promising response rates and survival data in patients with iCCA, especially in non-metastatic disease.

Key Points

• Percutaneous hepatic perfusion (PHP) offers an additional locoregional therapy strategy for the treatment of unresectable primary or secondary intrahepatic malignancies.

• PHP is a standardised and safe procedure that provides promising response rates and survival data in patients with intrahepatic cholangiocarcinoma (iCCA), especially in non-metastatic disease.

• Side effects seem to be tolerable and comparable to other systemic or local treatment strategies.

Razumilava N, Gores GJ (2014) Cholangiocarcinoma. Lancet 383:2168–2179. https://doi.org/10.1016/S0140-6736(13)61903-0 CrossRefPubMedPubMedCentral

DeOliveira ML, Cunningham SC, Cameron JL et al (2007) Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 245:755–762. https://doi.org/10.1097/01.sla.0000251366.62632.d3 CrossRefPubMedPubMedCentral

Bridgewater J, Lopes A, Palmer D et al (2016) Quality of life, long-term survivors and long-term outcome from the ABC-02 study. Br J Cancer 114:965–971. https://doi.org/10.1038/bjc.2016.64 CrossRefPubMedPubMedCentral

Kim JH, Won HJ, Shin YM, Kim KA, Kim PN (2011) Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol 196:W205–W209. https://doi.org/10.2214/AJR.10.4937

Xu H-X, Wang Y, Lu MD, Liu LN (2012) Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma. Br J Radiol 85:1078–1084. https://doi.org/10.1259/bjr/24563774 CrossRefPubMedPubMedCentral

Park SY, Kim JH, Yoon HJ, Lee IS, Yoon HK, Kim KP (2011) Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol 66:322–328. https://doi.org/10.1016/j.crad.2010.11.002

Vogl TJ, Naguib NN, Nour-Eldin NE et al (2012) Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. Int J Cancer 131:733–740. https://doi.org/10.1002/ijc.26407

Kuhlmann JB, Euringer W, Spangenberg HC et al (2012) Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol 24:437–443. https://doi.org/10.1097/MEG.0b013e3283502241 PubMedCrossRef

Hoffmann RT, Paprottka PM, Schön A et al (2012) Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 35:105–116. https://doi.org/10.1007/s00270-011-0142-x CrossRefPubMed

10.

Rafi S, Piduru SM, El-Rayes B et al (2013) Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol 36:440–448. https://doi.org/10.1007/s00270-012-0463-4 CrossRefPubMed

11.

Hughes MS, Zager J, Faries M et al (2016) Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol 23:1309–1319. https://doi.org/10.1245/s10434-015-4968-3 CrossRefPubMed

12.

Kirstein MM, Marquardt S, Jedicke N, et al (2017) Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors. J Cancer Res Clin Oncol: 1–9. https://doi.org/10.1007/s00432-017-2461-z

13.

Vogl TJ, Koch SA, Lotz G et al (2017) Percutaneous isolated hepatic perfusion as a treatment for isolated hepatic metastases of uveal melanoma: patient outcome and safety in a multi-centre study. Cardiovasc Intervent Radiol 40:864–872. https://doi.org/10.1007/s00270-017-1588-2 CrossRefPubMed

14.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026 CrossRefPubMed

15.

Burgmans MC, de Leede EM, Martini CH, Kapiteijn E, Vahrmeijer AL, van Erkel AR (2016) Percutaneous isolated hepatic perfusion for the treatment of unresectable liver malignancies. Cardiovasc Intervent Radiol 39:801–814. https://doi.org/10.1007/s00270-015-1276-z

16.

Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281. https://doi.org/10.1056/NEJMoa0908721 CrossRefPubMed

17.

Boehm LM, Jayakrishnan TT, Miura JT et al (2015) Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol 111:213–220. https://doi.org/10.1002/jso.23781 CrossRefPubMed

18.

Ray CE Jr, Edwards A, Smith MT et al (2013) Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 24:1218–1226. https://doi.org/10.1016/j.jvir.2013.03.019

19.

Currie BM, Soulen MC (2017) Decision making: intra-arterial therapies for cholangiocarcinoma-TACE and TARE. Semin Intervent Radiol 34:92–100. https://doi.org/10.1055/s-0037-1602591 CrossRefPubMedPubMedCentral

20.

Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS (2015) Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol 41:120–127. https://doi.org/10.1016/j.ejso.2014.09.007

21.

Moeslein FM, McAndrew EG, Appling WM et al (2014) Evaluation of Delcath Systems’ Generation 2 (GEN 2) melphalan hemofiltration system in a porcine model of percutaneous hepatic perfusion. Cardiovasc Intervent Radiol 37:763–769. https://doi.org/10.1007/s00270-013-0826-5 CrossRefPubMedPubMedCentral

22.

Leech BF, Carter CJ (1998) Falsely elevated INR results due to the sensitivity of a thromboplastin reagent to heparin. Am J Clin Pathol 109:764–768CrossRefPubMed

23.

Schultz NJ, Slaker RA, Rosborough TK (1991) The influence of heparin on the prothrombin time. Pharmacotherapy 11:312–316PubMed

24.

Doherty B, Nambudiri VE, Palmer WC (2017) Update on the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep 19:2. https://doi.org/10.1007/s11894-017-0542-4 CrossRefPubMed

25.

Schweitzer N, Vogel A (2015) Systemic therapy of cholangiocarcinoma: from chemotherapy to targeted therapies. Best Pract Res Clin Gastroenterol 29:345–353. https://doi.org/10.1016/j.bpg.2015.01.002 CrossRefPubMed

26.

Pingpank JF, Libutti SK, Chang R et al (2005) Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 23:3465–3474. https://doi.org/10.1200/JCO.2005.00.927

27.

Forster MR, Rashid OM, Perez M, Choi J, Chaudhry T, Zager JS (2014) Percutaneous hepatic perfusion with melphalan for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience. J Surg Oncol 109:434–439. https://doi.org/10.1002/jso.23501

28.

Yamamoto M, Zager JS (2014) Isolated hepatic perfusion for metastatic melanoma. J Surg Oncol 109:383–388. https://doi.org/10.1002/jso.23474 CrossRefPubMed

29.

Abbott AM, Doepker MP, Kim Y et al (2017) Hepatic progression-free and overall survival after regional therapy to the liver for metastatic melanoma. Am J Clin Oncol https://doi.org/10.1097/COC.0000000000000356

30.

Melphalan for use with the hepatic delivery system treatment in patients with unresectable hepatocellular carcinoma or intra hepatic cholangiocarcinoma - full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02415036?term=delcath&rank=3. Accessed 11 Sep 2017

31.

Sequential Melphalan for use with hepatic delivery system treatment followed by Sorafenib in patients with unresectable HCC - full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02406508?term=delcath&rank=. Accessed 11 Sep 2017

32.

Percutaneous hepatic perfusion vs best alternative care in patients with hepatic-dominant ocular melanoma - full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02678572?term=delcath&rank=5. Accessed 11 Sep 2017

33.

Vogl TJ, Zangos S, Scholtz JE et al (2014) Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. Rofo 186:937–944. https://doi.org/10.1055/s-0034-1366081 CrossRefPubMed

34.

Percutaneous hepatic perfusion vs. cisplatin/gemcitabine in patients with intrahepatic cholangiocarcinoma - full text view - ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03086993. Accessed 1 Sep 2017

Title: Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival
Authors: Steffen Marquardt
Martha M. Kirstein
Roland Brüning
Martin Zeile
Pier Francesco Ferrucci
Warner Prevoo
Boris Radeleff
Hervé Trillaud
Lambros Tselikas
Emilio Vicente
Philipp Wiggermann
Michael P. Manns
Arndt Vogel
Frank K. Wacker
Publication date: 01-04-2019
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 4/2019
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-018-5729-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival

Abstract

Objectives

Patients and methods

Results

Discussion

Key Points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Patients and methods

Results

Discussion

Key Points

Please log in to get access to this content

Other articles of this Issue 4/2019

Intra-individual comparison of gadolinium-enhanced MRI using pseudo-golden-angle radial acquisition with gadoxetic acid-enhanced MRI for diagnosis of HCCs using LI-RADS

Extracardiac findings on coronary computed tomography angiography in patients without significant coronary artery disease

Prospective multimodal imaging assessment of locally advanced cervical cancer patients administered by chemoradiation followed by radical surgery—the “PRICE“ study 2: role of conventional and DW-MRI

Gastric cancer and imaging biomarkers: Part 1 – a critical review of DW-MRI and CE-MDCT findings

Transvenous pulmonary chemoembolization (TPCE) for palliative or neoadjuvant treatment of lung metastases

Microvessel ultrasound of neonatal brain parenchyma: feasibility, reproducibility, and normal imaging features by superb microvascular imaging (SMI)